1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): SEPTEMBER 7, 2001
HALSEY DRUG CO., INC.
695 NO. PERRYVILLE ROAD, ROCKFORD, ILLINOIS
(815-399-2060)
Incorporated under the laws of Commission File Number I.R.S. Employer Identification Number
State of New York 1-10113 11-0853640
2
ITEM 5 OTHER EVENTS
On September 7, 2001, the Company announced that the U.S. Drug
Enforcement Administration ("DEA") has filed a notice in the Federal Register
regarding the Company's application for registration to manufacture Schedule II
controlled substances. The Company, which has previously received approval from
the DEA to manufacture Schedule III-N controlled substances at its Culver,
Indiana facility, intends immediately to commence the installation of the
necessary additional security measures in preparation for the anticipated DEA
inspection in sixty days. If the application is approved, of which there can be
no assurance, the Company would begin manufacturing certain controlled substance
active ingredients for use in the manufacture of pain management products.
In a related announcement, on September 7, 2001, the Company announced
that the DEA has filed a notice in the Federal Register regarding the Company's
application for registration to import certain controlled substances. If the
application is approved, of which there can be no assurance, the Company would
be one of only a very small number of companies allowed to directly import raw
materials for processing into controlled substances.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press release dated September 7, 2001
announcing the Company is seeking
registration from the DEA to manufacture
Schedule II controlled substances.
99.2 Press release dated September 7, 2001
announcing the Company is seeking
registration from the DEA to import
controlled substances.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
HALSEY DRUG CO., INC.
By: /s/ Michael Reicher
-------------------------------------------
Michael Reicher
President and Chief Executive Officer
Date: September 7, 2001